サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1386577

人工多能性幹細胞市場レポート：2030年までの動向、予測、競合分析

Induced Pluripotent Stem Cell Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

人工多能性幹細胞市場レポート：2030年までの動向、予測、競合分析
出版日: 2023年10月12日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

人工多能性幹細胞の動向と予測

世界の人工多能性幹細胞市場は、2024年から2030年までのCAGRが10.3%で、2030年までに推定26億米ドルに達すると予想されています。この市場の主な促進要因は、がん罹患率の上昇、幹細胞研究に対する財政投資の拡大、胚性幹細胞（ESC）と比較した人工多能性幹細胞（iPS細胞）の多くの利点です。世界の人工多能性幹細胞市場の将来は、研究・学術機関、バイオテクノロジー・製薬会社、病院・診療所市場でのビジネスチャンスにより有望視されています。

人工多能性幹細胞市場の洞察

Lucintelは、慢性疾患は世界中に広がっているため、予測期間中、医薬品開発・発見が最大のセグメントであり続けると予測しています。

アジア太平洋は、幹細胞ベースの研究に対する堅調で費用対効果の高い注目、経済の拡大、医療戦略の改善、個別化治療の有望性に対する認識の高まりにより、予測期間中に最も速い成長が見込まれます。

本レポートでは、以下の11の主要な質問に回答している：

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
  • Q.2.どの分野がより速いペースで成長するのか、またその理由は？
  • Q.3.今後成長が加速すると思われる地域とその理由は？
  • Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
  • Q.5.この市場におけるビジネスリスクと競合の脅威は？
  • Q.6.この市場における新たな動向とその理由は？
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は？
  • Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界の人工多能性幹細胞市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018年～2023年）と予測（2024年～2030年）
  • 世界の人工多能性幹細胞市場動向（2018年～2023年）と予測（2024年～2030年）
  • ワークフロー別の世界の人工多能性幹細胞市場
    • 再プログラミング
    • 細胞培養
    • 細胞の特性評価/分析
    • エンジニアリング
    • その他
  • 用途別の世界の人工多能性幹細胞市場
    • 創薬と発見
    • 再生医療
    • 毒物学研究
    • その他
  • 最終用途別の世界の人工多能性幹細胞市場
    • 研究・学術機関
    • バイオテクノロジー・製薬会社
    • 病院・クリニック

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界の人工多能性幹細胞市場
  • 北米の人工多能性幹細胞市場
  • 欧州の人工多能性幹細胞市場
  • アジア太平洋の人工多能性幹細胞市場
  • その他地域の人工多能性幹細胞市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • ワークフロー別の世界の人工多能性幹細胞市場の成長機会
    • 用途別の世界の人工多能性幹細胞市場の成長機会
    • 最終用途別の世界の人工多能性幹細胞市場の成長機会
    • 地域別の世界の人工多能性幹細胞市場の成長機会
  • 世界の人工多能性幹細胞市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界の人工多能性幹細胞市場の能力拡大
    • 世界の人工多能性幹細胞市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Lonza
  • Axol Bioscience
  • Evotec
  • Hitachi
  • REPROCELL
  • Merck
  • REPROCELLS
  • Fate Therapeutics
  • Thermo Fisher Scientific
  • StemCellsFactory III
目次

Induced Pluripotent Stem Cell Trends and Forecast

The future of the global induced pluripotent stem cell market looks promising with opportunities in the research & academic institute, biotechnology & pharmaceutical company, and hospital & clinic markets. The global induced pluripotent stem cell market is expected to reach an estimated $2.6 billion by 2030 with a CAGR of 10.3% from 2024 to 2030. The major drivers for this market are rising prevalence of cancer, amplified financial investments in stem cell research, and the numerous benefits of induced pluripotent stem cells (iPSCs) compared to embryonic stem cells (ESCs).

A more than 150-page report is developed to help in your business decisions.

Induced Pluripotent Stem Cell by Segment

The study includes a forecast for the global induced pluripotent stem cell by workflow, application, end use, and region.

Induced Pluripotent Stem Cell Market by Workflow [Shipment Analysis by Value from 2018 to 2030]:

  • Reprogramming
  • Cell Culture
  • Cell Characterization / Analysis
  • Engineering
  • Others

Induced Pluripotent Stem Cell Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Drug Development & Discovery
  • Regenerative Medicine
  • Toxicology Studies
  • Others

Induced Pluripotent Stem Cell Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Research & Academic Institutes
  • Biotechnology & Pharmaceutical Companies
  • Hospitals & Clinics

Induced Pluripotent Stem Cell Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Induced Pluripotent Stem Cell Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies induced pluripotent stem cell companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the induced pluripotent stem cell companies profiled in this report include-

  • Lonza
  • Axol Bioscience
  • Evotec
  • Hitachi
  • Reprocell
  • Merck
  • Reprocells
  • Fate Therapeutics
  • Thermo Fisher Scientific
  • Stemcellsfactory III

Induced Pluripotent Stem Cell Market Insights

Lucintel forecasts that drug development & discovery will remain the largest segment over the forecast period because the chronic illnesses are spreading throughout the world.

APAC is expected to witness fastest growth over the forecast period due to robust, cost-effective focus on stem cell-based research, the expansion of economies, improvements in healthcare strategies, and the increasing recognition of the promise of personalized treatments.

Features of the Global Induced Pluripotent Stem Cell Market

Market Size Estimates: Induced pluripotent stem cell market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Induced pluripotent stem cell market size by workflow, application, end use, and region in terms of value ($B).

Regional Analysis: Induced pluripotent stem cell market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different workflow, application, end use, and regions for the induced pluripotent stem cell market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the induced pluripotent stem cell market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the induced pluripotent stem cell market size?

Answer: The global induced pluripotent stem cell market is expected to reach an estimated $2.6 billion by 2030.

Q.2 What is the growth forecast for induced pluripotent stem cell market?

Answer: The global induced pluripotent stem cell market is expected to grow with a CAGR of 10.3% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the induced pluripotent stem cell market?

Answer: The major drivers for this market are rising prevalence of cancer, amplified financial investments in stem cell research, and the numerous benefits of induced pluripotent stem cells (iPSCs) compared to embryonic stem cells (ESCs).

Q4. What are the major segments for induced pluripotent stem cell market?

Answer: The future of the global induced pluripotent stem cell market looks promising with opportunities in the research & academic institute, biotechnology & pharmaceutical company, and hospital & clinic markets.

Q5. Who are the key induced pluripotent stem cell market companies?

Answer: Some of the key induced pluripotent stem cell companies are as follows:

  • Lonza
  • Axol Bioscience
  • Evotec
  • Hitachi
  • Reprocell
  • Merck
  • Reprocells
  • Fate Therapeutics
  • Thermo Fisher Scientific
  • Stemcellsfactory III

Q6. Which induced pluripotent stem cell market segment will be the largest in future?

Answer: Lucintel forecasts that drug development & discovery will remain the largest segment over the forecast period because the chronic illnesses are spreading throughout the world.

Q7. In induced pluripotent stem cell market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness fastest growth over the forecast period due to robust, cost-effective focus on stem cell-based research, the expansion of economies, improvements in healthcare strategies, and the increasing recognition of the promise of personalized treatments.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the induced pluripotent stem cell market by workflow (reprogramming, cell culture, cell characterization / analysis, engineering, and others), application (drug development & discovery, regenerative medicine, toxicology studies, and others), end use (research & academic institutes, biotechnology & pharmaceutical companies, and hospitals & clinics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Induced Pluripotent Stem Cell Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Induced Pluripotent Stem Cell Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Induced Pluripotent Stem Cell Market by Workflow
    • 3.3.1: Reprogramming
    • 3.3.2: Cell Culture
    • 3.3.3: Cell Characterization / Analysis
    • 3.3.4: Engineering
    • 3.3.5: Others
  • 3.4: Global Induced Pluripotent Stem Cell Market by Application
    • 3.4.1: Drug Development & Discovery
    • 3.4.2: Regenerative Medicine
    • 3.4.3: Toxicology Studies
    • 3.4.4: Others
  • 3.5: Global Induced Pluripotent Stem Cell Market by End Use
    • 3.5.1: Research & Academic Institutes
    • 3.5.2: Biotechnology & Pharmaceutical Companies
    • 3.5.3: Hospitals & Clinics

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Induced Pluripotent Stem Cell Market by Region
  • 4.2: North American Induced Pluripotent Stem Cell Market
    • 4.2.1: North American Induced Pluripotent Stem Cell Market by Application: Drug Development & Discovery, Regenerative Medicine, Toxicology Studies, and Others
    • 4.2.2: North American Induced Pluripotent Stem Cell Market by End Use: Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, and Hospitals & Clinics
  • 4.3: European Induced Pluripotent Stem Cell Market
    • 4.3.1: European Induced Pluripotent Stem Cell Market by Application: Drug Development & Discovery, Regenerative Medicine, Toxicology Studies, and Others
    • 4.3.2: European Induced Pluripotent Stem Cell Market by End Use: Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, and Hospitals & Clinics
  • 4.4: APAC Induced Pluripotent Stem Cell Market
    • 4.4.1: APAC Induced Pluripotent Stem Cell Market by Application: Drug Development & Discovery, Regenerative Medicine, Toxicology Studies, and Others
    • 4.4.2: APAC Induced Pluripotent Stem Cell Market by End Use: Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, and Hospitals & Clinics
  • 4.5: ROW Induced Pluripotent Stem Cell Market
    • 4.5.1: ROW Induced Pluripotent Stem Cell Market by Application: Drug Development & Discovery, Regenerative Medicine, Toxicology Studies, and Others
    • 4.5.2: ROW Induced Pluripotent Stem Cell Market by End Use: Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, and Hospitals & Clinics

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Induced Pluripotent Stem Cell Market by Workflow
    • 6.1.2: Growth Opportunities for the Global Induced Pluripotent Stem Cell Market by Application
    • 6.1.3: Growth Opportunities for the Global Induced Pluripotent Stem Cell Market by End Use
    • 6.1.4: Growth Opportunities for the Global Induced Pluripotent Stem Cell Market by Region
  • 6.2: Emerging Trends in the Global Induced Pluripotent Stem Cell Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Induced Pluripotent Stem Cell Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Induced Pluripotent Stem Cell Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Lonza
  • 7.2: Axol Bioscience
  • 7.3: Evotec
  • 7.4: Hitachi
  • 7.5: REPROCELL
  • 7.6: Merck
  • 7.7: REPROCELLS
  • 7.8: Fate Therapeutics
  • 7.9: Thermo Fisher Scientific
  • 7.10: StemCellsFactory III